Elicio Therapeutics, Inc.

Market Cap: N/A
Industry: Pharmaceuticals & Biotechnology
ISIN: US28657F1030

USD

7.61

-0.5 (-6.17%)

Feb 05

NAS

View all stocks in this country

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Comparison

Company

Score

Quality

Valuation

Financial

Technical

NanoString Technologies, Inc.

Enzo Biochem, Inc.

Avrobio, Inc.

Elicio Therapeutics, Inc.

Eliem Therapeutics, Inc.

BioXcel Therapeutics, Inc.

YS Biopharma Co. Ltd.

Athira Pharma, Inc.

Turnstone Biologics Corp.

Vaccinex, Inc.

Affimed NV

Why is Elicio Therapeutics, Inc. ?

Unrated Stock - No Analysis Available

Real-Time Research Report

Verdict Report

No Data Found

Is Elicio Therapeutics, Inc. for you?

High Risk, Low Return

Absolute

Risk Adjusted

Volatility

Elicio Therapeutics, Inc.

-17.46%

0.00

78.61%

S&P 500

13.99%

0.81

19.85%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

-100.00%

EBIT Growth (5y)

6.74%

EBIT to Interest (avg)

-27.45

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-2.03

Sales to Capital Employed (avg)

0.04

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

14.83%

ROCE (avg)

ROE (avg)

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

14.08

EV to EBIT

-2.36

EV to EBITDA

-2.42

EV to Capital Employed

-11.65

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

-508.10%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bearish

Mildly Bullish

RSI

No Signal

Bollinger Bands

Mildly Bearish

Bullish

Moving Averages

Bearish (Daily)

KST

Bearish

Bullish

Dow Theory

Mildly Bullish

No Trend

OBV

Mildly Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

8What is working for the Company

RAW MATERIAL COST(Y)

Fallen by 0% (YoY

DEBT-EQUITY RATIO (HY)

Lowest at -391.82 %

OPERATING PROFIT(Q)

Highest at USD -9.81 MM

PRE-TAX PROFIT(Q)

Highest at USD -9.7 MM

NET PROFIT(Q)

Highest at USD -9.7 MM

-8What is not working for the Company

INTEREST(HY)

At USD 0.37 MM has Grown at 335.29%

Here's what is working for Elicio Therapeutics, Inc.

Operating Profit

Highest at USD -9.81 MM

in the last five periods

MOJO Watch

Near term Operating Profit trend is positive

Operating Profit (USD MM)

Pre-Tax Profit

Highest at USD -9.7 MM

in the last five periods

MOJO Watch

Near term Pre-Tax Profit trend is positive

Pre-Tax Profit (USD MM)

Net Profit

Highest at USD -9.7 MM

in the last five periods

MOJO Watch

Near term Net Profit trend is positive

Net Profit (USD MM)

Debt-Equity Ratio

Lowest at -391.82 %

in the last five Semi-Annual periods

MOJO Watch

The company has been reducing its borrowing as compared to equity capital

Debt-Equity Ratio

Raw Material Cost

Fallen by 0% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Elicio Therapeutics, Inc.

Interest

At USD 0.37 MM has Grown at 335.29%

over previous Semi-Annual period

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (USD MM)